M. D. Anderson Cancer Center - News Releases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Experimental Gene Therapy Successful In Certain Lymphomas And Leukemia
Study results of CD19-directed chimeric antigen receptor (CAR) therapy
using the Sleeping Beauty non-viral transduction system to modify T
cells has demonstrated further promise in patients with advanced
hematologic malignancies. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 8, 2014 Category: Cancer & Oncology Source Type: news
Targeting MicroRNA May Benefit Some Ovarian And Breast Cancer Patients
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 8, 2014 Category: Cancer & Oncology Source Type: news
PRM-151 Therapy Well Tolerated In Patients With Advanced Myelofibrosis
A study that investigated the potential of the compound PRM-151 (PRM)
for reducing progressive bone marrow fibrosis (scarring) in patients
with advanced myelofibrosis has shown initial positive results.
Myelofibrosis is a life-threatening bone marrow cancer. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 8, 2014 Category: Cancer & Oncology Source Type: news
Study Shows Improved Survival In Aggressive Acute Myeloid Leukemia
Patients who relapse in their battle with acute myeloid leukemia (AML)
may benefit from a phase three study of therapies that combine an
existing agent, cytarabine, with a newer compound, vosaroxin. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 7, 2014 Category: Cancer & Oncology Source Type: news
Combination Therapy Shown As Effective For Higher-Risk MDS/AML Patients
A phase two study that investigated the potential of the drugs
azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two
therapies in combination may be an effective frontline treatment regimen
for patients with higher-risk forms of myelodysplastic syndrome and
acute myeloid leukemia. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 7, 2014 Category: Cancer & Oncology Source Type: news
MD Anderson Names New Chief Financial Officer
The University of Texas MD Anderson Cancer Center has announced that Weldon Gage will become the institution's vice president and chief financial officer effective Jan. 12. Gage brings with him a proven record of enhancing financial performance throughout an 18-year health care career. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 3, 2014 Category: Cancer & Oncology Source Type: news
MD Anderson researcher receives top Italian science award
Peter Friedl, M.D., Ph.D., professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center, has received one of Italy's top scientific awards for his work in imaging and cancer growth, metastasis and therapy response. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 1, 2014 Category: Cancer & Oncology Source Type: news
Eight MD Anderson faculty named as AAAS fellows
Their responsibilities may range from exploring the intricacies of
biostatistics to bringing new drugs more rapidly to the patient, but
eight faculty members from The University of Texas MD Anderson Cancer Center all share one honor - being named as Fellows by the American Association for the Advancement of Science. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 24, 2014 Category: Cancer & Oncology Source Type: news
Novel Regulatory Mechanism For Cell Division Found
A protein kinase or enzyme known as PKM2 has proven to control cell division,
potentially providing a molecular basis for tumor diagnosis and treatment. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 21, 2014 Category: Cancer & Oncology Source Type: news
MD Anderson, Memorial Hermann launch innovative breast program
Memorial
Hermann and The University of Texas MD Anderson Cancer Center have
launched operations under their recently formed partnership to offer
high-quality, specialized breast screening and diagnostic services at a network
of community breast care centers in the greater Houston area. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 20, 2014 Category: Cancer & Oncology Source Type: news
Power behind 'master' gene for cancer discovered
A study at MD Anderson led by Mong-Hong Lee, Ph.D., a professor of molecular and cellular oncology,
has demonstrated the significance of CSN6 in regulating Myc which may
very well open up a new pathway for treating and killing tumors. The
study results are published in this month's issue of Nature Communications. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 19, 2014 Category: Cancer & Oncology Source Type: news
Metabolic 'reprogramming' by the p53 gene family leads to tumor regression
We examined an alternative approach by manipulating the p53 family members, p63 and p73," said Flores.
Flores described two "warring" versions of p63 and p73 that are at odds when it comes to tumor suppression. One version, known as transactivation domain-bearing, is structurally and functionally similar to p53 in their ability to suppress tumors. The other version, which lacks this transactivation domain, actually prevents p53 from stopping tumor growth. Transactivation domains are specific regions within a protein known as a transcription factor that effect further downstream cellular responses.
"The p53 family int...
Source: M. D. Anderson Cancer Center - News Releases - November 17, 2014 Category: Cancer & Oncology Source Type: news
Hedgehog signaling pathway for breast cancer identified
MD Anderson study points to long non-coding RNA as potential therapeutic target
Molecules called long non-coding RNAs (lncRNAs) have been implicated in breast cancer but exactly why they cause metastasis and tumor growth has been little understood...until now.
Scientists at The University of Texas MD Anderson Cancer Center report that hedgehog, a unique cell signaling pathway known to contribute to many types of cancer, may be behind breast cancer metastasis. This molecular message service works with the lncRNA known as BCAR4 giving the genetic green light for tumor growth.
"Our study of BCAR4 and the hedgehog signa...
Source: M. D. Anderson Cancer Center - News Releases - November 13, 2014 Category: Cancer & Oncology Source Type: news
MD Anderson's David M. Gershenson, MD, Receives IGCS's Award for Excellence in Gynecologic Oncology
For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society's (IGCS) Award of Excellence.
Gershenson, professor and past chair of the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, received the award at the IGCS's 15th Biennial Meeting in Melbourne, Australia. William J. Hoskins, MD., of Memorial Sloan Kettering, also was honored with the distinction.The IGCS is a not-for-prof...
Source: M. D. Anderson Cancer Center - News Releases - November 10, 2014 Category: Cancer & Oncology Source Type: news
Number of Young Patients with Newly Diagnosed Colorectal Cancer Anticipated to Double
In the next 15 years, more than one in 10 colon cancers
and nearly one in four rectal cancers will be diagnosed in patients younger than
the traditional screening age, according to researchers at The University of Texas MD Anderson Cancer
Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - November 5, 2014 Category: Cancer & Oncology Source Type: news